

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA lenalidomide for multiple myeloma

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No equality issues have been identified.
--

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

N/A

3. Has any change to the draft scope been agreed to highlight potential equality issues?
--

N/A

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
--

No.

Technology appraisals: Scoping

Equality impact assessment for the proposed single technology appraisal of Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171).

Issue date: September 2013

Approved by Associate Director (name): Elisabeth George

Date: 05/09/2013

Technology appraisals: Scoping

Equality impact assessment for the proposed single technology appraisal of Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171).

Issue date: September 2013